Wells Fargo Initiates Coverage On Vor Biopharma with Overweight Rating, Announces Price Target of $30

Wells Fargo analyst Sadia Rahman initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Overweight rating and announces Price Target of $30.